Your AI-Trained Oncology Knowledge Connection!
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.
A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.
Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.
The gene for an anticancer drug was successfully transduced in high-grade gliomas, which resulted in an improvement in overall survival, according to data from a phase I trial of Toca 511.
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.
Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.
Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.
Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.
Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.
Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.
Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.
Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.
Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.
Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.
A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.
Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).
Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).
H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).
There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.
Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.
Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.
Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute (NCI), discusses the potential for immunotherapy in hepatocellular carcinoma (HCC).
Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.
Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.
George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).
Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.
The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.
